ArticleACS omega2026
Noninvasive Blood Glucose Monitoring with Machine Learning Enhanced Transmittance Spectroscopy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a widespread metabolic disease in which the body's inability to regulate blood glucose levels leads to severe health complications. Current limitations in noninvasive glucose sensing make finger-prick glucometers the standard for personal monitoring despite their discomfort and challenges for frequent measurements. By combining machine learning techniques with transmittance spectroscopy, this study presents a noninvasive approach for estimating BGL in personal healthcare. The system employs multispectral transmittance measurements at 650, 808, and 940 nm to evaluate glucose concentrations in aqueous solutions. Simulation of light absorption in skin layers and in vitro experiments identified 940 nm as the optimal wavelength, offering high sensitivity with minimal interference from water absorption. Using this wavelength, an in vivo system based on transmittance spectroscopy was developed for noninvasive glucose measurement. A machine learning pipeline incorporating ensemble models was implemented to predict glucose levels from optical data. Trained on 200 clinical samples obtained from the in vivo experimental setup, the XGBoost model outperformed other algorithms, achieving an
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.